Natera Partners with Angiex to Track Response to Novel Cancer Therapy — Natera, Inc.

Event summary

Natera and Angiex will collaborate to assess the response to AGX101, an investigational Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC), using Natera’s Signatera test for circulating tumor DNA (ctDNA).
AGX101 is currently in a Phase I clinical trial for unresectable, locally advanced, or metastatic solid tumors.
The collaboration aims to explore whether longitudinal ctDNA measurements can complement imaging and improve treatment response monitoring.
Natera’s Signatera test provides personalized ctDNA measurements that may offer additional insights beyond traditional radiologic assessments.

The big picture

This collaboration aligns with the growing trend of leveraging advanced biomarker testing to enhance the precision and effectiveness of cancer therapies. Natera’s Signatera test is increasingly being recognized as a valuable tool in the oncology space, while Angiex’s AGX101 represents a novel approach to targeting solid tumors. The partnership could set a precedent for how biotech companies integrate molecular diagnostics into drug development pipelines.

What we're watching

Clinical Validation: How the integration of ctDNA monitoring will impact the clinical validation of AGX101 and its potential approval pathway.
Market Differentiation: Whether Natera’s Signatera can establish itself as a critical tool for monitoring response to novel cancer therapies, enhancing its market position.
Therapeutic Efficacy: The pace at which AGX101 demonstrates efficacy in targeting both tumor cells and tumor vasculature, which could influence its adoption in oncology.